Always a privilege to work with Alicia Morgans, MD, MPH and the UroToday.com team. Thank you for being committed to spreading educational content in GU Cancers

Very important paper confirming surrogacy of cPFS and rPFS in mHSPC with OS. Great work. We need ICE!!! ⁦Michael Morris⁩ ⁦The PCCTC⁩ ⁦Christopher Sweeney, MBBS⁩

Should we radiate the primary in high volume metastatic hormone sensitive #prostatecancer ? #JasonEfstathiou says yes! Daniel E Spratt says maybe sometimes. Patient selection based on biology seems a happy medium. #USProstateCancerConsortium OncLive.com Prostate Cancer Foundation Neeraj Agarwal, MD, FASCO

Andrew Armstrong Emmanuel Antonarakis Misha Beltran Alan H Bryce Phillip Koo, MD Sandy Srinivas Michael Carducci Charles Ryan Tanya Dorff GU Cancer Research Program @HuntsmanCancer PCF Science Sumanta K. Pal, MD, FASCO Petros Grivas OncLive.com Rana McKay Tian Zhang, MD, MHS Shilpa Gupta Daniel E Spratt #USProstateCancerConference Tian Zhang, MD, MHS and Alan H Bryce argue for or against ARPI+PARPi vs PARPi Mono Rx in metastatic #prostatecancer with HRRm after prior ARPI. Case can be made for both combo or PAPPi alone👇. OncLive.com Misha Beltran UroToday.com OncoAlert

Andrew Armstrong Emmanuel Antonarakis Misha Beltran Alan H Bryce Phillip Koo, MD Sandy Srinivas Michael Carducci Charles Ryan Tanya Dorff GU Cancer Research Program @HuntsmanCancer PCF Science Sumanta K. Pal, MD, FASCO Petros Grivas #USProstateCancerConference OncLive.com 👉Question: should serial tumor genomic testing be done in advanced #prostatecancer ? Point and counterpoint by Rana McKay and #EvanYu 👇Misha Beltran

#USProstateCancerConference Outstanding debate between Andrew Armstrong & Emmanuel Antonarakis on the use of PARPi+ARPI combo in HRRm + versus HRRm- patients👉balancing AEs with efficacy and looking for biomarkers in HRRm- pts👇Misha Beltran Alan H Bryce

#USProstateCancerConference OncLive.com at NYC👉 Esteemed group of investigators discussing challenging areas in treatment of #prostatecancer : Excellent talk by Jeremie Calais on PSMA PET impact in BCR setting. Alan H Bryce Phillip Koo, MD

Great data David Olmos Elena Castro
Practical results that can inform our decisions and thinking in the clinic. Congratulations!

In our study of Pembro monotherapy in #prostatecancer , MSI-H appeared to enhance pembro response with improved outcomes with as TMB increases. Thrilled to see this paper getting published!
⁦Adam M. Kase, MD⁩ ⁦Dr. Winston Tan⁩ ⁦Alan H Bryce⁩ ⁦ nature.com/articles/s4139…

So proud of Syed Arsalan Ahmed Naqvi Irbaz Riaz MD,MS,MBI,PhD for Merit award ⭐️⭐️ Mayo GU research fellow

Welcome aboard Kristin Higgins. This is great news for City of Hope . I look forward to working with you.

Congratulation to all the recipients. Keep an eye on hem onc fellow Oluyesi Abidoye and Syed Arsalan Ahmed Naqvi, both at Mayo Clinic Comprehensive Cancer Center. Arsalan hasn’t even begun residency yet and already has 2 ASCO merit awards. More to come from both of these rising talents.

I’m excited to share that I have made the move to City of Hope. We are building a new cancer center in Phoenix with the goal of making top quality academic cancer care accessible to all Arizonans.

Eloquent discussion from Andrea Apolo, M.D. National Cancer Institute synthesizing data from #EV302 & #CM901 . Loved the fact that she offered a strong, definitive opinion on the 'winner' in the battle between these options. Also (not shown) great outline of remaining questions - what comes after EVP?…

For the first time, the pillars of advanced urothelial cancer treatment are shaken. EV-302 trial shows EV+Pem is superior (ORR, PFS and OS) to platinum-based chemotherapy in 1st line mUC
Congrats Tom Powles and coauthors!!! #ESMO23

Early salvage RT is as effective as adjuvant RT in PSA failure after RP. Final results presented by N. Clarke at #ESMO23 . ESMO - Eur. Oncology Prostate Cancer Foundation ΕΟΠΕ Neeraj Agarwal, MD, FASCO Petros Grivas Sumanta K. Pal, MD, FASCO Tian Zhang, MD, MHS Eleni Efstathiou Uromigos UroToday.com European Association of Urology (EAU) ASCO @

Fabio Schutz Toni Choueiri, MD Tom Powles Laurence Albiges Guillermo de Velasco Sumanta K. Pal, MD, FASCO Neeraj Agarwal, MD, FASCO You can read more in the paper published today in Cancer Discovery concurrently with the presentation: doi.org/10.1158/2159-8…

Adverse events profile and mechanism of action of xaluritamig. #ESMO23